New 'Living Drug' trial targets tough blood cancers
NCT ID NCT07196111
Summary
This early-phase study is testing the safety and initial effectiveness of a new type of CAR-T cell therapy called BAFFR CAR-T in adults with B-cell blood cancers that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight the cancer. The main goals are to find a safe dose and see if the treatment can shrink or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.